Allos gets NDA rolling for efaproxiral
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allos will complete rolling NDA for its radiation sensitizer efaproxiral (RSR13) by year-end. The final component includes clinical information supporting use of efaproxiral as an adjunct to radiation therapy for the treatment of brain metastases from breast cancer. Allos initiated the submission in August with non-clinical information, and submitted CMC data in September
You may also be interested in...
Allos Limits RSR13 Brain Metastases NDA To Breast Cancer; User Fee In June
Allos expects its radiation sensitizer RSR13 (efaproxiral) to receive a priority review for the treatment of brain metastases from breast cancer, placing the user fee goal date in June.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.